Literature DB >> 27212398

Targeting glutamate to treat schizophrenia: lessons from recent clinical studies.

Katherine Beck1, Daniel C Javitt2,3, Oliver D Howes4,5.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2016        PMID： 27212398     DOI： 10.1007/s00213-016-4318-6

Source DB:  PubMed          Journal:  Psychopharmacology (Berl)        ISSN： 0033-3158            Impact factor:   4.530


× No keyword cloud information.
  27 in total

Review 1.  Perspectives on the mGluR2/3 agonists as a therapeutic target for schizophrenia: Still promising or a dead end?

Authors:  Meng-Lin Li; Xi-Quan Hu; Feng Li; Wen-Jun Gao
Journal:  Prog Neuropsychopharmacol Biol Psychiatry       Date:  2015-02-24       Impact factor: 5.067

2.  Antipsychotic treatment resistance in schizophrenia associated with elevated glutamate levels but normal dopamine function.

Authors:  Arsime Demjaha; Alice Egerton; Robin M Murray; Shitij Kapur; Oliver D Howes; James M Stone; Philip K McGuire
Journal:  Biol Psychiatry       Date:  2013-07-25       Impact factor: 13.382

Review 3.  Glycine and N-methyl-D-aspartate receptors: physiological significance and possible therapeutic applications.

Authors:  W Danysz; C G Parsons
Journal:  Pharmacol Rev       Date:  1998-12       Impact factor: 25.468

4.  Control of NMDA receptor activation by a glycine transporter co-expressed in Xenopus oocytes.

Authors:  S Supplisson; C Bergman
Journal:  J Neurosci       Date:  1997-06-15       Impact factor: 6.167

5.  Effects of the glycine reuptake inhibitors bitopertin and RG7118 on glycine in cerebrospinal fluid: results of two proofs of mechanism studies in healthy volunteers.

Authors:  Carsten Hofmann; Flavia Pizzagalli; Christophe Boetsch; Daniela Alberati; Larry Ereshefsky; Stanford Jhee; Alain Patat; Bruno Boutouyrie-Dumont; Meret Martin-Facklam
Journal:  Psychopharmacology (Berl)       Date:  2016-05-14       Impact factor: 4.530

6.  Anterior cingulate glutamate levels related to clinical status following treatment in first-episode schizophrenia.

Authors:  Alice Egerton; Stefan Brugger; Marie Raffin; Gareth J Barker; David J Lythgoe; Philip K McGuire; James M Stone
Journal:  Neuropsychopharmacology       Date:  2012-07-04       Impact factor: 7.853

7.  Activation of mGlu2/3 receptors as a new approach to treat schizophrenia: a randomized Phase 2 clinical trial.

Authors:  Sandeep T Patil; Lu Zhang; Ferenc Martenyi; Stephen L Lowe; Kimberley A Jackson; Boris V Andreev; Alla S Avedisova; Leonid M Bardenstein; Issak Y Gurovich; Margarita A Morozova; Sergey N Mosolov; Nikolai G Neznanov; Alexander M Reznik; Anatoly B Smulevich; Vladimir A Tochilov; Bryan G Johnson; James A Monn; Darryle D Schoepp
Journal:  Nat Med       Date:  2007-09-02       Impact factor: 53.440

8.  Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans. Psychotomimetic, perceptual, cognitive, and neuroendocrine responses.

Authors:  J H Krystal; L P Karper; J P Seibyl; G K Freeman; R Delaney; J D Bremner; G R Heninger; M B Bowers; D S Charney
Journal:  Arch Gen Psychiatry       Date:  1994-03

9.  The practical management of refractory schizophrenia--the Maudsley Treatment REview and Assessment Team service approach.

Authors:  K Beck; R McCutcheon; M A P Bloomfield; F Gaughran; T Reis Marques; J MacCabe; S Selvaraj; D Taylor; O D Howes
Journal:  Acta Psychiatr Scand       Date:  2014-09-09       Impact factor: 6.392

10.  A neurobiological hypothesis for the classification of schizophrenia: type A (hyperdopaminergic) and type B (normodopaminergic).

Authors:  Oliver D Howes; Shitij Kapur
Journal:  Br J Psychiatry       Date:  2014-07       Impact factor: 9.319
View more
  7 in total

1.  Memantine add-on to antipsychotic treatment for residual negative and cognitive symptoms of schizophrenia: a meta-analysis.

Authors:  Taro Kishi; Yuki Matsuda; Nakao Iwata
Journal:  Psychopharmacology (Berl)       Date:  2017-05-15       Impact factor: 4.530

Review 2.  Structure, Function, and Pharmacology of Glutamate Receptor Ion Channels.

Authors:  Kasper B Hansen; Lonnie P Wollmuth; Derek Bowie; Hiro Furukawa; Frank S Menniti; Alexander I Sobolevsky; Geoffrey T Swanson; Sharon A Swanger; Ingo H Greger; Terunaga Nakagawa; Chris J McBain; Vasanthi Jayaraman; Chian-Ming Low; Mark L Dell'Acqua; Jeffrey S Diamond; Chad R Camp; Riley E Perszyk; Hongjie Yuan; Stephen F Traynelis
Journal:  Pharmacol Rev       Date:  2021-10       Impact factor: 18.923

3.  Dopamine and glutamate in schizophrenia: biology, symptoms and treatment.

Authors:  Robert A McCutcheon; John H Krystal; Oliver D Howes
Journal:  World Psychiatry       Date:  2020-02       Impact factor: 49.548

4.  Cannabidiol modulation of hippocampal glutamate in early psychosis.

Authors:  Aisling O'Neill; Luciano Annibale; Grace Blest-Hopley; Robin Wilson; Vincent Giampietro; Sagnik Bhattacharyya
Journal:  J Psychopharmacol       Date:  2021-04-16       Impact factor: 4.153

Review 5.  Kynurenine Pathway of Tryptophan Metabolism: Regulatory and Functional Aspects.

Authors:  Abdulla A-B Badawy
Journal:  Int J Tryptophan Res       Date:  2017-03-15

6.  Glutamate Concentration in the Superior Temporal Sulcus Relates to Neuroticism in Schizophrenia.

Authors:  Johanna Balz; Yadira Roa Romero; Julian Keil; Florian Schubert; Bernd Ittermann; Ralf Mekle; Christiane Montag; Jürgen Gallinat; Daniel Senkowski
Journal:  Front Psychol       Date:  2018-05-07

7.  N-methyl-D-aspartate receptor availability in first-episode psychosis: a PET-MR brain imaging study.

Authors:  Katherine Beck; Atheeshaan Arumuham; Mattia Veronese; Barbara Santangelo; Colm J McGinnity; Joel Dunn; Robert A McCutcheon; Stephen J Kaar; Nisha Singh; Toby Pillinger; Faith Borgan; James Stone; Sameer Jauhar; Teresa Sementa; Federico Turkheimer; Alexander Hammers; Oliver D Howes
Journal:  Transl Psychiatry       Date:  2021-08-12       Impact factor: 6.222
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.